A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT ID: NCT01343628

Last Updated: 2012-05-31

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-01-31
• Study Completion Date: 2012-04-30

Brief Summary

Alcohol dependence, or "alcoholism", affects approximately 14 million Americans. Currently, only three pharmacotherapies (disulfiram, naltrexone, and acamprosate) have been approved for the treatment of alcohol dependence and these medications are, at best, moderately successful. Thus, there is a great need for the examination of other biological systems, which contribute/influence the drug reward/addiction pathways within the brain, such that the discovery of new targets and new pharmacotherapies will be possible. Other biological systems in addition to dopamine, such as serotonin, and norepinephrine (NE) are thought to be important in several aspects of addiction, including reward, craving and depression.

This study will examine the effects of a 5 day course of atomoxetine (a selective NE transporter (NET) inhibitor) (80 mg/day; Strattera or placebo) on alcohol-elicited craving and sensitivity to alcohol. The novelty of this study is that of atomoxetine and the fact that it targets NET, neither of which has heretofore been examined in the context of alcohol dependence. It is hopeful that this study, of 64 total individuals, will provide the PI with sufficient preliminary data to submit a subsequent R01 application to study atomoxetine and the involvement of specific single nucleotide polymorphisms within the NET gene on alcohol-related phenotypes in alcohol dependent and non-dependent populations. The long-term objective of this research is to develop more efficacious treatment interventions for alcohol abuse and dependence.

Detailed Description

Design:

NET genotype groups for rs11648486 SNP (CC 61%; CT 33%; TT 4%) (e.g., C/C and C/T) will be compared to one another in a 2 (NET Genotype: C/C vs. C/T & T/T) x 2 (Medication: atomoxetine 80 mg/day (~ vs. placebo) x 3 (Drink: Drink 1, 2, and 3) mixed factorial repeated measures design using PROC MIXED in SAS by calculating difference scores. Of interest are the possible interactions of the NET SNPs and atomoxetine on cue-elicited craving and the rewarding effects of alcohol across trials.

Conditions

Alcohol-induced Cue-craving; Alcohol Sensitivity

Keywords

Alcohol, atomoxetine, Strattera, alcohol dependence, alcoholism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Placebo, Atomoxetine

Group Type: PLACEBO_COMPARATOR

Placebo Comparator

Intervention Type: DRUG

16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5

Atomoxetine, Placebo

Group Type: ACTIVE_COMPARATOR

Active Comparator: Atomoxetine, Placebo

Intervention Type: DRUG

16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.

Interventions

Placebo Comparator

16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5

Intervention Type: DRUG

Active Comparator: Atomoxetine, Placebo

16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Males and females age 21 - 45, as verified upon the presentation of a valid, government issued form of ID
• Current DSM-IV diagnosis of alcohol dependence using the Mini International Neuropsychiatric Interview (MINI). Which is a shortened form of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders or SCID. The MINI will also be used to exclude patients with other diagnoses.
• Participants do not meet DSM-IV criteria for any current (i.e., criteria met at any point in the past 30 days) Axis I disorder (including ADHD treated with medication), other than cocaine dependence or those listed above, that warrants treatment or would preclude safe participation in the protocol
• Not currently take medications that are contraindicated for concurrent use with alcohol;
• No subjects who have trouble reading the English language or visual or hearing problems that may interfere with the collection of data;
• No recurring past history of severe hypertension, glaucoma, hyperthyroidism, circulatory disease, hepatitis, chronic liver disease, ulcer disease, seizure disorder, brain disease, cardiac disease, obstructed bowel, or other current treatment of medical conditions that could determine ineligibility;
• Female subjects must not be breastfeeding and must not be pregnant, as indicated by a pregnancy test that will be conducted immediately prior dispensing of medication.
• Subjects have to have normal EKGs results
• Pulse less than 100 beats per minute
• Participants have to weigh between 125-290; weighing between 125-195 lbs (57 - 88.5 kg)

Exclusion Criteria

• Significant medical illness (including severe hypertension) as determined by history and/or complete physical examination. (Note: Presence of mild to moderate chronic diseases not otherwise specifically excluded, that are well controlled by medications/interventions will not be considered clinically significant. However the presence of medical disease that is not well controlled will be considered exclusionary.)
• tachycardia
• seizure disorder
• prior history of myocardial infarction
• Clinically significant cardiovascular disease that precludes safe participation
• hepatic or renal impairment; (ie: liver or kidney enzymes > 3x normal limits)
• pregnant
• currently using MAO inhibitors within 14 days

• narrow angle glaucoma
• currently taking antidepressants or have taken within the last month
• currently taking pressor agents such as:
• Alprenolol
• Carteolol
• Levobunolol
• Mepindolol
• Metipranolol
• Nadolol
• Oxprenolol
• Penbutolol
• Pindolol
• Propranolol
• Sotalol
• Timolol
• Acebutolol
• Atenolol
• Betaxolol
• Bisoprolol[16]
• Esmolol
• Metoprolol
• Nebivolol
• Carvedilol
• Celiprolol
• Labetalol
• Butaxamine

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

Sponsor Role: collaborator

University of Virginia

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Heather M Haughey, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Virginia

Locations

Center for Addiction Research and Education

Charlottesville/ Richmond, Virginia, United States

Countries

United States

Other Identifiers

K01AA015331

Identifier Type: NIH

Identifier Source: secondary_id

View Link

13464

Identifier Type: -

Identifier Source: org_study_id